Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Exercise Therapy for Women With ANOCA (ANOCA Exercise)

24 de julio de 2026 actualizado por: NHS Greater Glasgow and Clyde

Exercise Therapy for Women With ANOCA: a Randomised, Controlled Trial

Angina is a feeling of chest pain or discomfort which can happen if there is reduced blood flow to the heart. Patients can experience angina with no obstructive coronary arteries (ANOCA) which is a difficult condition to treat (ie relieve angina) since few randomised, controlled therapy trials have been undertaken for ANOCA. Until now, angina has been mainly studied in men even though women are at least two-fold more likely than men to experience ANOCA.

In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. Resistance exercise has not been assessed in ANOCA and it offers an important opportunity to study non drug alternatives to treatment for women.

This study will use a resistance based exercise programme to investigate if symptoms of ANOCA can be improved in women. It will recruit at least 76 patients (maximum 152 patients) across 13 hospitals in the UK and the Netherlands.

The study will use a randomised wait list control design. This means all participants will be offered the intervention, but the randomisation will decide when they undergo it.

It is part of a platform of trials for women with ANOCA. We are also setting up a drug study called ANOCA Therapy and a cohort study called ANOCA- Diagnosis.

Descripción general del estudio

Descripción detallada

There is a gap in knowledge on evidence-based therapy for ANOCA. Stratified medicine is a population-level diagnostic approach for identifying endotypes in a heterogenous population of all-comers. An endotype is defined as a subtype of a condition, which must be characterised by a distinct functional or pathophysiological mechanism.

Use of quantitative noninvasive and invasive diagnostic methods, such as magnetic resonance imaging and coronary function tests involving acetylcholine testing, enables more accurate identification and discrimination of causal endotypes of ANOCA. This is especially relevant for women with ANOCA who have historically been under-recognised.

Quantitative diagnostic methods should bring an end to empirical therapy, therapeutic nihilism and sex disparities in ANOCA.

Precision medicine is different. Precision medicine targets the individual (and their endotype) with a mechanism informed therapy. Accordingly, in this Wellcome Leap Visible project, we will employ a stratified medicine diagnostic approach in women with suspected ANOCA undergoing invasive CFTs in multiple hospitals and then employ a precision medicine strategy by offering each woman an endotype-informed therapy option.

Resistance exercise has not been previously investigated in ANOCA and it therefore represents a novel therapeutic option. This lifestyle intervention will increase the range of trial options, maximize patient choice for participation, and facilitate timely delivery of this project. The beneficial effects of resistance exercise on cardiovascular function have recently been endorsed in a Scientific Statement from the American Heart Association and further supported by a systematic review and favourable experience in our recent randomized trial in Long COVID.

In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. In 19 men with coronary artery disease and endothelial dysfunction, indicated by abnormal acetylcholine-induced coronary vasoconstriction, a randomized controlled trial of aerobic exercise training demonstrated improvements in endothelium-dependent vasodilatation both in epicardial coronary vessels and in resistance vessels. The intervention involved an exercise program six times per day for at least 10 minutes. These results were promising but came with major limitations: no women were included in the study and the exercise program is both burdensome and impractical.

Resistance exercise has not been assessed in ANOCA. Inclusion of a non-CTIMP (lifestyle intervention) brings strategic advantages to our ANOCA platform. A non-medicinal intervention provides an accessible therapy option for women of child-bearing age and for those who may prefer not to participate in an investigational drug trial. This non-CTIMP may also become an option for women who withdraw from a CTIMP, or who complete a CTIMP and are willing to continue into a second trial. The basket trial of resistance exercise may include participants who have completed a precision medicine CTIMP who then wish to participate in the resistance exercise trial or vice versa.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

76

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Basildon, Reino Unido
        • Basildon University Hospital
      • Bath, Reino Unido
        • Royal United Hospital Bath
      • Cambridge, Reino Unido
        • Royal Papworth Hospital
      • Glasgow, Reino Unido, G51 4TF
        • Queen Elizabeth University Hospital Clinical Research Facility
        • Contacto:
      • Leeds, Reino Unido
        • Leeds General Infirmary
      • London, Reino Unido
        • Kings College Hospital
      • London, Reino Unido
        • Brompton Hospital
      • London, Reino Unido
        • Guy and St Thomas Hospital
      • Newcastle upon Tyne, Reino Unido
        • Freeman Hospital
        • Contacto:
          • Vijay Kunadian
      • Nottingham, Reino Unido
        • Nottingham City Hospital
      • Sunderland, Reino Unido
        • Sunderland Royal Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Angina with no obstructive coronary arties (ANOCA)
  2. Myocardial perfusion reserve or coronary flow reserve recorded within three years
  3. Seattle Angina Questionnaire frequency score ≤60
  4. Duke Activity Status Index ≤34
  5. Female sex

Exclusion Criteria:

  1. Age <18 years
  2. Unable to provide informed consent
  3. - Unable to comply with the protocol
  4. Pregnancy
  5. Currently undertaking resistance exercise activities

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intervention
Allocated to exercise intervention first
Participants will undergo daily resistance based exercise for 8 weeks
Comparador activo: Control
Allocated to exercise intervention second
Participants will undergo daily resistance based exercise for 8 weeks

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Seattle Angina Questionnaire
Periodo de tiempo: Change from Baseline to Week 9
The Seattle Angina Questionnaire a validated 19-item patient-reported survey used to measure coronary artery disease and angina treatment efficacy. Patients will complete on paper or electronically. The scores range from 0 to 100, with higher scores indicating less frequent angina, improved function, and better quality of life.
Change from Baseline to Week 9

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Myocardial perfusion reserve (MPR)
Periodo de tiempo: Change from baseline to week 9
The ratio of maximum blood flow in the heart muscle under stress compared to resting flow
Change from baseline to week 9
Handgrip strength using hand dynamometer
Periodo de tiempo: Change from baseline to week 9
Measured in Kgs. This is used as a proxy for overall body strength with lower measures indicating less strength.
Change from baseline to week 9
Short Physical Performance Battery (SPPB)
Periodo de tiempo: Change from baseline to week 9
Used as a proxy for fitness
Change from baseline to week 9
Brief Illness perception Questionnaire (Brief IPQ)
Periodo de tiempo: Change from baseline to week 9
A nine-item scale designed to rapidly assess the cognitive and emotional representations of illness. It consists of 9 items: 8 are scored on a 0-10 scale, and item 9 is an open-ended question assessing perceived causes. The total score (0-80) is calculated by summing the first 8 items, with items 3, 4, and 7 reverse scored. Higher scores generally reflect a more threatening perception of the illness
Change from baseline to week 9
Patient Health Questionnaire-4 of (PHQ4)
Periodo de tiempo: Change from Baseline to Week 9
An ultra-brief screening tool used to assess core symptoms of anxiety and depression. Higher scores indicate greater feelings of anxiety and depression.
Change from Baseline to Week 9
Duke Activity Status Index (DASI)
Periodo de tiempo: From Baseline to Week 9
A 12-item, self-administered questionnaire used to estimate a patient's functional capacity and peak oxygen uptake. Scores range from 0 to 58.2, with higher scores indicating better physical fitness and lower risk
From Baseline to Week 9
EQ-5D (EQ-5D-5L)
Periodo de tiempo: Change from Baseline to Week 9

The EQ-5D evaluates health across 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). It yields three metrics: a 5-digit health profile string, a weighted index value, and a 0-100 self-rated Visual Analogue Scale (VAS) score.

For the 5-digit health profile string higher individual numbers indicate worse health problems.

For the weighted index value a score of 1 indicates perfect health, while 0 represents death.

For the visual analogue score higher numbers here indicate better health

Change from Baseline to Week 9
International Physical Activity Questionnaire (IPAQ)
Periodo de tiempo: Change from Baseline to Week 9
Used to obtain comparable estimates of physical activity between populations and countries. Higher scores indicate greater physical activity.
Change from Baseline to Week 9
Fatigue severity scale questionnaire
Periodo de tiempo: Change from Baseline to Week 9
Rates level of fatigue. 9 statements assess how fatigue impacts daily life. Each statement is rated on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). Higher scores indicate greater fatigue.
Change from Baseline to Week 9
Short Form Post-Exercise Malaise Questionnaire
Periodo de tiempo: Change from Baseline to Week 9
measures symptom exacerbation by assessing frequency and severity of symptoms. Higher scores reflect a stronger indication of post exercise malaise.
Change from Baseline to Week 9
Episodes of care (primary, secondary, physiotherapy, rehabilitation)
Periodo de tiempo: Week 9
How many times participants engaged with services
Week 9
Hospitalisation for any reason by electronic health record review (where available) up to 4 months (Visit 3)
Periodo de tiempo: Week 17
Review of medical notes to see if the patient has been in hospital
Week 17

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Colin Berry, The University of Glasgow

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

14 de septiembre de 2026

Finalización primaria (Estimado)

30 de junio de 2029

Finalización del estudio (Estimado)

30 de junio de 2029

Fechas de registro del estudio

Enviado por primera vez

20 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de julio de 2026

Publicado por primera vez (Actual)

29 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

A decision will be made by the TSC once the study has ended.

Marco de tiempo para compartir IPD

After the study has completed

Criterios de acceso compartido de IPD

Bone fide collaboration request

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir